Importantly, the combination of CSII and CGM technologies has resulted in increasing level of automation of insulin delivery in response to sensor glucose readings, ranging from no automation (sensor-augmented pump [SAP] therapy) to algorithm-driven suspension of basal insulin for actual and/or impending hypoglycemia (predictive low glucose management, PLGM), algorithm-driven infusion of basal insulin (hybrid closed loop [HCL] insulin delivery) or algorithm-driven infusion of both basal insulin and correction boluses (advanced hybrid closed loop [AHCL] insulin delivery). This evidence concerns the gene INS and Hypoglycemia.